Lustral (Sertraline) is commonly used across conditions characterized by periods of heightened symptoms of emotional distress. This medication is utilized to treat Major Depressive Disorder, Panic Disorder, Obsessive-Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD), Social Anxiety Disorder, and Premenstrual Dysphoric Disorder (PMDD).

It is applied across domains where additional symptomatic support is needed, particularly when symptoms interfere with daily functioning. The medication helps ease the overall burden of chronic symptoms, assisting with maintaining functional stability and a sense of routine. It is relevant in situations requiring temporary assistance in symptom stabilization, for instance, by moderating pronounced symptoms of severe mood instability associated with the luteal phase of the menstrual cycle or reducing the intensity of unexpected panic attacks.

---

Quick Fact: Support for Compulsive and Intrusive Thoughts Lustral is commonly used to help manage symptoms associated with repetitive, unwanted thoughts and the subsequent anxiety-driven compulsive urges in Obsessive-Compulsive Disorder.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Lustral — Official Regulatory Information

Eligibility Scope Populations for whom use is allowed (as stated in label): Adults (18+ years) for all approved indications and Pediatric patients (6–17 years) only for Obsessive-Compulsive Disorder (OCD). Populations for whom use is contraindicated: Patients taking Monoamine Oxidase Inhibitors (MAOIs), including Pimozide, or those with known Hypersensitivity to sertraline.

Age-related eligibility rules Use is not established for children under six years of age. Young adults (under 25) have a mandated regulatory warning regarding increased risk of suicidal thoughts. Use in older adults requires caution, as this population may have an increased risk of hyponatremia.

Condition-specific eligibility rules Use is not recommended in Severe Hepatic Impairment due to a lack of clinical data. Patients with Mild or Moderate Hepatic Impairment require conditional use. The label requires Caution in those with a history of seizure disorders or risk factors for QTc prolongation. Use must be avoided in patients with untreated anatomically narrow angles.

Pregnancy and lactation eligibility status (if explicitly documented) Use during pregnancy is permissible only if the potential benefit justifies the potential risk to the fetus. Sertraline transfers into breast milk in small amounts, and the official status requires weighing risk against benefit.

Connection to the overall eligibility profile Official regulatory documents define Lustral eligibility through a structured framework that imposes absolute prohibitions, specific age- and indication-based limits, and conditional use criteria for patients with pre-existing hepatic, cardiac, or psychiatric conditions.

Interactions with other medicines and products

Contraindicated Combinations

Lustral (sertraline) must not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs), including linezolid and methylene blue, due to the risk of serious reactions, including Serotonin Syndrome. A minimum 14-day washout period is required when switching between sertraline and an MAOI. Co-administration is also contraindicated with pimozide and thioridazine due to the potential for increased drug levels and cardiac rhythm disturbances.

Pharmacokinetic and Pharmacodynamic Interactions

Sertraline is a mild inhibitor of the enzyme CYP2D6, which may lead to increased exposure of co-administered medicines metabolized by this pathway, such as certain tricyclic antidepressants.

Pharmacodynamic interactions increase the risk of certain adverse effects. Concomitant use with other serotonergic medicines (e.g., triptans, tramadol, fentanyl, and the herbal product St. John's Wort) increases the risk of Serotonin Syndrome. Additionally, co-administration with drugs that affect blood clotting, such as warfarin, NSAIDs, or aspirin, increases the risk of bleeding due to sertraline's effect on platelet function. Patients taking warfarin must have their coagulation status (INR) closely monitored upon starting or stopping Lustral.

Food and Population-Specific Notes

Regulatory information notes that co-administration with food increases the absorption of sertraline. Concomitant use with alcohol is not recommended. Patients with hepatic impairment may experience significantly higher sertraline exposure, which should be considered.

Selective Inhibition of Serotonin Reuptake

Lustral (sertraline) operates by acting as a highly selective inhibitor of the Serotonin Transporter (SERT) protein on presynaptic neurons. This molecular action blocks the normal process of serotonin reabsorption, resulting in an increased concentration and prolonged presence of the neurotransmitter in the synaptic cleft. This engagement of the core monoamine pathway initiates a targeted adjustment of neurotransmitter levels that underlies the resultant alteration in signaling.

Driving Long-Term Adaptive Signaling

The initial blockade of SERT is the first step in a complex mechanistic cascade that leads to long-term adaptive changes in the serotonergic system. The sustained modulation of serotonin availability triggers neuroplasticity, altering receptor sensitivity and gene expression in relevant neural centers. This mechanism results in the establishment of a modulated state within targeted central pathways, shaping the resulting change in central nervous system activity.

Influencing Central Physiological Processes

The drug's activity affects systems where serotonergic signaling is prominent, including pathways associated with sleep-wake cycles, appetite control, and the regulation of certain physiological responses. This action modulates the intensity of physiological responses and leads to altered activity within the autonomic and limbic systems.

Lustral (Sertraline) is administered via the oral route as a once-daily dose, which may be taken either in the morning or evening. The tablets are taken with or without food. If the oral concentrate solution is used, it must be diluted immediately before administration with a half cup of water, ginger ale, lemonade, lemon/lime soda, or orange juice, avoiding other liquids such as grapefruit juice.

Official Dosing and Adjustment

Treatment is initiated at a low dose, typically 50 mg per day for Major Depressive Disorder and adult Obsessive-Compulsive Disorder, and 25 mg per day for Panic Disorder, Posttraumatic Stress Disorder, and Social Anxiety Disorder. Subsequent dosage adjustments are made in 25 mg or 50 mg increments at intervals of at least one week, depending on patient response, with the maximum dose generally not exceeding 200 mg per day.

Administration Detail	Standard Administration Guidelines
Standard Frequency	Once daily
Titration Interval	Minimum of one week
Maximum Dose	200 mg/day (Most Indications)
Hepatic Impairment	Starting and maximum dose is half the usual amount in mild impairment

For pediatric patients (aged 6 to 12) being treated for OCD, the initial dose is 25 mg per day. If a dose is missed, the standard protocol is to skip the missed dose and take the next dose at the regular time, rather than doubling the dose. Treatment cessation requires the dose to be gradually reduced over time.

Research Evidence / Overview of Studies for Lustral

Evidence for Use in Major Depressive Disorder (MDD)

Research exploring Major Depressive Disorder primarily utilizes short-term Randomized Controlled Trials (RCTs). These studies were conducted in research exploring how symptoms change over defined time intervals, typically lasting between 6 and 12 weeks, in adult populations. Studies examined outcomes related to symptom intensity, global clinical status, and daily functioning or activity level. Long-term maintenance trials, some lasting up to 20 months, explored outcomes related to the recurrence or relapse of a major depressive episode following continued treatment. The results apply primarily to the populations studied in the original trials.

Evidence for Use in Obsessive-Compulsive Disorder (OCD)

Research into Obsessive-Compulsive Disorder (OCD) primarily utilizes short-term (10-12 week) Randomized Controlled Trials (RCTs). These studies included both adult patients and specific trials for pediatric populations (children and adolescents). Researchers focused on outcomes related to symptom intensity of obsessions and compulsions using specific rating instruments. Long-term continuation studies were also explored, monitoring symptom patterns over a period of up to two years. Findings describe patterns observed in the studies, indicating that the required treatment duration and dosages for OCD were often higher than those used in depression trials.

What is Still Uncertain About the Research Base for Lustral

While the evidence base for Lustral is large, research highlights what is known and what is still uncertain across several areas:

• Long-Term Durability: There is limited information for long-term outcomes, particularly beyond one to two years, across all approved indications.
• Comparative Evidence: Comparative evidence of Lustral versus non-drug interventions (like specific psychotherapies) is lacking in many head-to-head study designs.
• Population Specificity: Subgroup findings are uncertain, especially regarding patients with complex comorbidities or highly treatment-resistant forms of the conditions. Some studies conducted in broader primary care settings showed less defined patterns of symptom change compared to highly controlled specialty settings, suggesting evidence quality varies across studies based on patient selection.

Common questions about Lustral (FAQ)

Q: Is Lustral the same medication as Zoloft?

Yes, Lustral is a brand name for the active ingredient sertraline hydrochloride. The trade name Zoloft also refers to medication containing sertraline hydrochloride. Therefore, both Lustral and Zoloft contain the exact same active pharmaceutical ingredient.

Q: What are the most commonly reported side effects when first starting Lustral?

Official product information notes that certain side effects tend to occur in the first stages of treatment. These commonly reported reactions include nausea, diarrhea, insomnia (trouble sleeping), dizziness, somnolence (drowsiness), and fatigue. Close clinical monitoring is typically advised for all adverse effects, particularly when starting the medication.

Q: How long do initial side effects, like nausea or restlessness, typically last?

Regulatory information indicates that the medication reaches steady-state blood levels in about one week, meaning the amount of drug in the body stabilizes around that time. While the specific duration of initial side effects is not listed, many reactions may lessen as the body adjusts to the medication over the first few weeks.

Q: Is weight gain or weight loss a possible side effect of Lustral?

Official regulatory documents list both decreased appetite (anorexia) and weight loss as possible adverse reactions. Weight gain is also a reported adverse reaction associated with this medication. The specific effect on an individual’s weight cannot be predicted.

Q: What are the signs of Serotonin Syndrome to watch for when taking Lustral?

Serotonin Syndrome is a serious condition linked to excessive serotonin activity, and official labeling documents list key signs to monitor. These signs include rapid changes like agitation, hallucinations, fever, excessive sweating, confusion, fast heartbeat, severe muscle stiffness or twitching, and loss of coordination.

Q: What is the typical time frame before a person might notice Lustral starting to work?

The body takes about one week for the drug to reach steady-state plasma levels, which is the point where the medication concentration becomes relatively stable. However, the full change in symptoms, or therapeutic benefit, may require several weeks to develop. Due to this timeframe, regulatory information specifies that dose adjustments should not occur in intervals shorter than one week.

Q: How long does it usually take to feel the 'full effect' or benefit of Lustral?

Clinical trials used to study the medication’s effectiveness for depression assessed changes in symptoms over periods ranging from 6 to 12 weeks. This indicates that the maximum therapeutic response and evaluation of the full benefit typically occur over this longer time frame.

Q: Is it possible for anxiety symptoms to temporarily worsen when starting Lustral?

Regulatory documents list anxiety and agitation as common adverse reactions. Official warnings also note that certain behavioral changes, sometimes called behavioral activation, may occur early on in treatment or following a dose adjustment.

Q: What happens if Lustral is stopped suddenly (discontinuation syndrome)?

Abrupt cessation of Lustral is not advised in regulatory information. Stopping suddenly can result in withdrawal symptoms, often referred to as discontinuation syndrome. Symptoms may include dizziness, sensory disturbances (like electric shock sensations), sleep problems, agitation, and anxiety.

Q: What does the research say about Lustral's effectiveness for Generalized Anxiety Disorder (GAD)?

Lustral is approved by regulatory bodies for the treatment of conditions like Social Anxiety Disorder and Panic Disorder. However, Generalized Anxiety Disorder (GAD) is not listed among the primary approved indications on the drug’s core regulatory labels.

Q: Does Lustral have a high risk of drug dependency or abuse?

Official regulatory documents state that Lustral (sertraline) is not classified as a controlled substance. Clinical data suggests a low potential for abuse. However, dependence is possible, and withdrawal symptoms can occur if the medication is stopped abruptly.

Q: What are the most common reasons patients stop taking Lustral?

Based on data from clinical trials, the most frequent reasons for stopping the drug in clinical trials, due to side effects, were nausea, diarrhea, insomnia, and ejaculation failure. These findings are listed in the adverse reaction profiles in official product information.

Q: What is the typical elimination half-life of Lustral?

Pharmacokinetic data available in regulatory labeling indicates that the average terminal elimination half-life of sertraline in the plasma is approximately 26 hours. The half-life refers to the time it takes for the concentration of the medication in the body to be reduced by half.

Q: What is known about Lustral's efficacy compared to a placebo in clinical trials for depression?

Clinical trials reviewed by regulatory bodies indicated that Lustral demonstrated superiority compared to placebo in relieving symptoms of depression. This finding was based on measurements of symptom severity using recognized scales, such as the Hamilton Depression Rating Scale.

Q: Does Lustral affect cognitive functions like memory or concentration?

The adverse reaction listings in official documents include central nervous system effects, such as confusion and memory impairment. These are reported events and are categorized under the potential effects of the medication.

Q: What is the guidance on driving or operating machinery while taking Lustral?

Official product information advises that patients should be cautioned regarding their ability to safely perform complex tasks. These tasks include driving or operating potentially hazardous machinery, and this caution should be maintained until the patient is certain the medication does not negatively affect their mental alertness or motor skills.

Q: Is it possible for Lustral to cause a false-positive result on certain drug screening tests?

Regulatory documents include information that some drug screening tests may show an incorrect, false-positive result for certain substances, such as benzodiazepines, in patients who are taking sertraline. This possibility is noted in the medication's warnings and precautions section.

Q: What is the connection between Lustral and premenstrual dysphoric disorder (PMDD)?

Sertraline is approved by regulatory bodies for the treatment of Premenstrual Dysphoric Disorder (PMDD). Official information notes that treatment options may involve daily dosing or dosing only during the luteal phase of the menstrual cycle.

Q: Why must Lustral be discontinued slowly, even after feeling better?

Official guidance indicates that the dose is typically reduced gradually over time. This approach is necessary to minimize the risk of developing withdrawal symptoms or a recurrence of the original symptoms after stopping the medication.

Q: What are the requirements for monitoring children and adolescents taking Lustral?

Official labeling, including boxed warnings, mandates close monitoring for clinical worsening and the development of suicidal thoughts and behaviors in pediatric and young adult patients. Furthermore, the regulatory information notes that monitoring weight and Body Mass Index (BMI) is an important part of clinical oversight.

How to Store and Dispose of Lustral?

To ensure product stability and safety, Lustral (sertraline) should be stored at controlled room temperature, generally between 15 to 30 C (59 to 86 F). The medication must be kept in its original container, tightly closed, and protected from excessive heat and moisture. Do not store the medicine in a bathroom.

Safety regulations mandate that all medication, including Lustral, must be kept completely out of sight and reach of children to prevent accidental ingestion.

Proper disposal is essential to prevent misuse and environmental harm. The recommended method for discarding unused or expired Lustral is through an official drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance, such as dirt or used coffee grounds, sealed in a bag or container, and then thrown in the household trash. This compound is officially noted as very toxic to aquatic life, emphasizing the need to avoid release into the environment through sewers or water sources.